BIOMAT Database Logo BIOMAT Database Logo

Discovery of DS79182026: A potent orally active hepcidin production inhibitor. 2017

Takeshi Fukuda, and Riki Goto, and Toshihiro Kiho, and Kenjiro Ueda, and Sumie Muramatsu, and Masami Hashimoto, and Anri Aki, and Kengo Watanabe, and Naoki Tanaka
Rare Disease & LCM Laboratories, Daiichi Sankyo Co, Ltd, 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan. Electronic address: fukuda.takeshi.zv@daiichisankyo.co.jp.

Hepcidin has emerged as the central regulatory molecule of systemic iron homeostasis. Inhibition of hepcidin could be a strategy favorable to treating anemia of chronic disease (ACD). We report herein the synthesis and structure-activity relationships (SARs) of a series of benzisoxazole compounds as orally active hepcidin production inhibitors. The optimization study of multi kinase inhibitor 1 led to a potent and bioavailable hepcidin production inhibitor 38 (DS79182026), which showed serum hepcidin lowering effects in a mouse IL-6 induced acute inflammatory model.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008298 Maleates Derivatives of maleic acid (the structural formula (COO-)-C
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008862 Microsomes, Liver Closed vesicles of fragmented endoplasmic reticulum created when liver cells or tissue are disrupted by homogenization. They may be smooth or rough. Liver Microsomes,Liver Microsome,Microsome, Liver
D002219 Carbamates Derivatives of carbamic acid, H2NC( Carbamate,Aminoformic Acids,Carbamic Acids,Acids, Aminoformic,Acids, Carbamic
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001583 Benzoxazoles Benzoxazole

Related Publications

Takeshi Fukuda, and Riki Goto, and Toshihiro Kiho, and Kenjiro Ueda, and Sumie Muramatsu, and Masami Hashimoto, and Anri Aki, and Kengo Watanabe, and Naoki Tanaka
Discovery of DS42450411 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4-aminopyrimidine derivatives.
November 2018, Bioorganic & medicinal chemistry letters,
Takeshi Fukuda, and Riki Goto, and Toshihiro Kiho, and Kenjiro Ueda, and Sumie Muramatsu, and Masami Hashimoto, and Anri Aki, and Kengo Watanabe, and Naoki Tanaka
Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor.
October 2016, ACS medicinal chemistry letters,
Takeshi Fukuda, and Riki Goto, and Toshihiro Kiho, and Kenjiro Ueda, and Sumie Muramatsu, and Masami Hashimoto, and Anri Aki, and Kengo Watanabe, and Naoki Tanaka
Discovery of SPH3127: A Novel, Highly Potent, and Orally Active Direct Renin Inhibitor.
August 2022, Journal of medicinal chemistry,
Takeshi Fukuda, and Riki Goto, and Toshihiro Kiho, and Kenjiro Ueda, and Sumie Muramatsu, and Masami Hashimoto, and Anri Aki, and Kengo Watanabe, and Naoki Tanaka
Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor.
November 2019, Acta pharmaceutica Sinica. B,
Takeshi Fukuda, and Riki Goto, and Toshihiro Kiho, and Kenjiro Ueda, and Sumie Muramatsu, and Masami Hashimoto, and Anri Aki, and Kengo Watanabe, and Naoki Tanaka
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
February 2008, Journal of medicinal chemistry,
Takeshi Fukuda, and Riki Goto, and Toshihiro Kiho, and Kenjiro Ueda, and Sumie Muramatsu, and Masami Hashimoto, and Anri Aki, and Kengo Watanabe, and Naoki Tanaka
Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor.
June 2002, Bioorganic & medicinal chemistry letters,
Takeshi Fukuda, and Riki Goto, and Toshihiro Kiho, and Kenjiro Ueda, and Sumie Muramatsu, and Masami Hashimoto, and Anri Aki, and Kengo Watanabe, and Naoki Tanaka
Discovery of a Novel, Potent, Orally Active, and Safe Inhibitor Targeting Human Mitochondrial RNA Polymerase.
April 2023, Journal of medicinal chemistry,
Takeshi Fukuda, and Riki Goto, and Toshihiro Kiho, and Kenjiro Ueda, and Sumie Muramatsu, and Masami Hashimoto, and Anri Aki, and Kengo Watanabe, and Naoki Tanaka
Discovery and characterization of a novel potent, selective and orally active inhibitor for mammalian ELOVL6.
March 2010, European journal of pharmacology,
Takeshi Fukuda, and Riki Goto, and Toshihiro Kiho, and Kenjiro Ueda, and Sumie Muramatsu, and Masami Hashimoto, and Anri Aki, and Kengo Watanabe, and Naoki Tanaka
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
May 2016, Journal of medicinal chemistry,
Takeshi Fukuda, and Riki Goto, and Toshihiro Kiho, and Kenjiro Ueda, and Sumie Muramatsu, and Masami Hashimoto, and Anri Aki, and Kengo Watanabe, and Naoki Tanaka
A potent and orally active HIV-1 integrase inhibitor.
March 2007, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!